Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00757510 · ClinicalTrials.gov registry record
Congenital Heart Disease Research Registry
A clinical trial, sponsored by Emory University.
- Terminated
- Registry status
- 861
- Enrollment target
NCT00757510: Clinical Trial study, sponsored by Emory University.
NCT00757510 is a clinical trial that was terminated before completion, run by Emory University. The registered enrollment target is 861 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00757510 was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- 861 participants
- Enrollment target
Study Summary
The Congenital Heart Disease Research Registry (CHDRR) is a program dedicated to understanding the etiology and improving the treatment of Congenital Heart Disease (CHD). This Registry will act as a central coordinating center for recruiting subjects with CHD and will provide infrastructure and guidelines for researchers studying the causes and treatment of CHD. Investigators working directly with the Registry will have access to biological, demographic and phenotype data from a significant pool of participants with CHD.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 861 participants |
| Start Date | 2008-01 |
| Est. Completion | 2010-02 |
Why NCT00757510 stopped before completion
NCT00757510 is an observational study that tracks outcomes without assigning an intervention. The registered 861 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00757510 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00757510 about?
NCT00757510 is a clinical study titled "Congenital Heart Disease Research Registry". The Congenital Heart Disease Research Registry (CHDRR) is a program dedicated to understanding the etiology and improving the treatment of Congenital Heart Disease (CHD). This Registry will act as a central coordinating center for recruiting subjects with CHD and will provide infrastructure and guid...
What is the current status of trial NCT00757510?
This trial is currently terminated. The enrollment target is 861 participants. The study started on 2008-01. Estimated completion is 2010-02.
Who is sponsoring clinical trial NCT00757510?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05914116 · 862 participants · Phase 1
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- NCT04541381 · 860 participants · NA
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
- NCT05211895 · 860 participants · Phase 3
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
- NCT06161025 · 860 participants · Phase 2
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia